How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

297 results for

adhd Bupropion

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

241. Memory Functioning and Antidepressant Treatment

. Condition or disease Intervention/treatment Phase Depression Major Depressive Disorder Drug: Escitalopram Drug: Bupropion XL Phase 3 Detailed Description: Purpose of the Present Study: The purpose of the present study is to comprehensively evaluate memory functioning of MDD patients before and after 8 weeks of antidepressant treatment with bupropion-XL or escitalopram. A neuropsychological test battery will incorporate multiple aspects of memory functioning including: short-term & working memory; verbal (...) of primary anxiety disorder, bipolar I or II disorder, or psychotic disorders Presence of anorexia nervosa or bulimia nervosa Presence or history of epilepsy or other seizure disorders Presence of significant Axis II disorder based on investigator judgment Presence of significant unstable medical condition Presence or past history of ADHD or significant learning disability ECTs (unilateral) within the past 12 months or bilateral ECT (ever) More than 2 failed adequate antidepressant treatments

2006 Clinical Trials

242. Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II

thoughts 10. Suicidal thoughts. Cutoff points:0 to 6- normal/symptom absent; 7 to 19- mild depression; 20 to 34- moderate depression; >34- severe depression. YMRS:a 11-item clinician-admin instrument assesses severity of mania. Symptoms rated: Elevated mood, Increased motor activity/energy, Sexual interest, Sleep, irritability, Speech, language/thought disorder, Content, Disruptive/aggressive behavior, Appearance, Insight. Each composed of five explicitly defined levels of severity. Severity ratings (...) Global Impression for Bipolar Disorders Overall Severity [ Time Frame: Baseline and 8 weeks ] 0-7 scale: rated on the following seven-point scale:) 0=not assessed, 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. This rating is based upon observed and reported symptoms, behavior, and function in the past seven days. Percentage of Participants With Clinical Global Impression for Bipolar

2005 Clinical Trials

243. Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients

Volunteers: No Criteria Inclusion Criteria: Schizophrenia or schizoaffective Disorder Taking olanzapine or clozapine for at least 6 months Weight gain of 7% over baseline or BMI greater than or equal to 27 Exclusion Criteria: Current treatment with methylphenidate, clonidine, tricyclic antidepressants, bupropion and venlafaxine Treatment with other medications known to cause weight gain unless weight stable on medication for 6 months Current treatment with other medications for weight loss unless weight (...) Collaborator: Eli Lilly and Company Information provided by (Responsible Party): Robert W. Buchanan, M.D., University of Maryland Study Details Study Description Go to Brief Summary: The study investigates the use of Atomoxetine in combination with exercise and a diet support group (Weight Watchers)to treat weight gain associated with Olanzapine or clozapine. All patients must be adults who have been diagnosed with Schizophrenia or Schizoaffective Disorder. Condition or disease Intervention/treatment Phase

2005 Clinical Trials

244. Naturalistic long-term use of methylphenidate in bipolar disorder. (Abstract)

Naturalistic long-term use of methylphenidate in bipolar disorder. Antidepressant use seems to be problematic in bipolar disorder. The dopaminergic agent, bupropion, seems to be equally effective to serotoninergic agents but with greater safety. Methylphenidate is a stimulant medication that is sometimes used as an antidepressant in bipolar adults and is frequently used in children with comorbid bipolar and attention-deficit disorder. There are no data available for the safety of long-term (...) methylphenidate in adults. A retrospective chart review of bipolar patients who received methylphenidate while attending a bipolar clinic was conducted. Data regarding side effects and symptoms were collected. Sixteen charts were reviewed. The mean duration of methylphenidate treatment was 14 months (+/-SD, +/-17.5 months; range, 1-60 months). Five had comorbid attention-deficit disorder, the remainder received the methylphenidate for depression. The mean dose was 16.3 mg/d (+/-SD, +/-8.7 mg/d; range, 5-40 mg

2006 Journal of Clinical Psychopharmacology

245. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. (Abstract)

relevant recent psychiatric sources (2000-2003).The described uses of the MAOI-stimulant combination have included treatment of refractory depression and the MAOI-related side effects of orthostatic hypotension and daytime sedation. No documented reports were found in the recent literature of hypertensive crises or fatalities occurring when the stimulant was cautiously added to the MAOI. Also presented here is another possible indication for this therapeutic regimen: treatment of attention-deficit (...) /hyperactivity disorder in an adult patient whose major depression had uniquely responded to the MAOI tranylcypromine.As in other fields of medicine, potentially hazardous medication combinations are utilized in psychiatry after cautiously weighing the danger of the treatment against the morbidity and risk of not adequately addressing the illness. Particularly, as the potential arrival of the apparently safer transdermal selegiline may increase the use of MAOIs, we feel this combination deserves additional

2004 Journal of Clinical Psychiatry

246. Atomoxetine use associated with onset of a motor tic. (Abstract)

Atomoxetine use associated with onset of a motor tic. Patients with attention-deficit/hyperactivity disorder (ADHD) are at increased risk for Tourette's Disorder and other tic disorders. Stimulant medications and bupropion have been associated with the onset or exacerbation of a tic disorder. The selective norepinephrine reuptake inhibitor, atomoxetine, has been proposed to be an alternative medication for patients with ADHD and a comorbid tic disorder. This paper reviews a case study in which (...) the onset of a motor tic was associated with a trial of the medication atomoxetine. Further research is needed to determine if atomoxetine is an appropriate alternative medication in patients with ADHD and a comorbid tic disorder.

2005 Journal of Child and Adolescent Psychopharmacology

247. Drug Treatment for Pathological Gambling

) Sharing Statement: Plan to Share IPD: No Plan Description: There is no plan to share individual participant data. Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Additional relevant MeSH terms: Layout table for MeSH terms Gambling Disruptive, Impulse Control, and Conduct Disorders Mental Disorders Bupropion Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane (...) English; Be able to give written informed consent. Exclusion Criteria: Evidence of current (past 3 months) substance misuse; Had a Hamilton Depression Rating Scale (HDRS)27 score of 18 or more (or a score on item 1 of greater than 2; Had a current eating disorder (except binge eating disorder); Had any history of seizures, or suicidal or aggressive behavior; Had a urine drug screen positive for stimulants, opiates, hallucinogens, or phencyclidine; Had a current or past psychotic disorder, bipolar

2003 Clinical Trials

248. Treatment of adult ADHD: Is current knowledge useful to clinicians?

Treatment of adult ADHD: Is current knowledge useful to clinicians? Treatment of adult ADHD: Is current knowledge useful to clinicians? Treatment of adult ADHD: Is current knowledge useful to clinicians? Torgersen T, Gjervan B, Rasmussen K CRD summary This review concluded there was good support for the pharmacological and psychotherapeutic treatment of attention deficit hyperactivity disorder in adults. It is likely that the review was affected by multiple sources of error and bias, which (...) means that the conclusions should not be regarded as reliable. Authors' objectives To review the literature on pharmacological and psychotherapeutic treatment for adult attention deficit hyperactivity disorder (ADHD) with a particular emphasis on comorbidity. Searching The following databases were searched to January 2007 and search terms were not reported: PubMed, EMBASE, PsycINFO and the Cochrane Library. References from included studies were also searched for relevant papers. Study selection

2008 DARE.

249. Comparing the efficacy of medications for ADHD using meta-analysis

Comparing the efficacy of medications for ADHD using meta-analysis Comparing the efficacy of medications for ADHD using meta-analysis Comparing the efficacy of medications for ADHD using meta-analysis Faraone S V, Biederman J, Spencer T J, Aleardi M CRD summary The authors concluded that the greater efficacy found for stimulants compared with nonstimulants in children with attention-deficit/hyperactivity disorder (ADHD) needs to be interpreted with caution in view of the impact of potential (...) confounding factors. There were limitations in the review process, but the authors’ conclusion appears appropriately cautious given the lack of head-to-head comparisons of different classes of ADHD drugs. Authors' objectives To compare the efficacy of drug treatments for attention-deficit/hyperactivity disorder (ADHD) in youths. Searching MEDLINE, PREMEDLINE, PubMed, ERIC, CINAHL, the Cochrane CENTRAL Register, e-psyche and Social Science Abstracts were searched for studies published after 1979

2006 DARE.

250. Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD

by Timothy Wilens, MD, Massachusetts General Hospital: ADHD Attention Deficit Hyperactivity Disorder Strattera Concerta Atomoxetine OROS Methylphenidate Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Methylphenidate Atomoxetine Hydrochloride Central Nervous (...) or disease Intervention/treatment Phase ADHD Attention Deficit Hyperactivity Disorder Drug: Atomoxetine and OROS Methylphenidate Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 94 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Efficacy and Safety/Tolerability of OROS MPH (Concerta) Plus Atomoxetine (ATMX) in Children and Adolescents (Age 6-17

2007 Clinical Trials

251. Atomoxetine Pilot Study in Preschool Children With ADHD

with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Atomoxetine Hydrochloride Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Adrenergic Agents Neurotransmitter Agents Physiological Effects of Drugs (...) Summary: The purpose of this study is to determine if atomoxetine (a common brand name is Strattera), a medicine that is used for treating older children with Attention Deficit and Hyperactivity Disorder (ADHD), is also safe and helpful for ADHD problems in young children. While atomoxetine is not approved by the FDA for use in children younger than 6 years, the FDA has given permission to study this drug in this age group. Condition or disease Intervention/treatment Phase Attention Deficit

2007 Clinical Trials

252. Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate

Numbers: 2003-P-000038 First Posted: March 14, 2006 Last Update Posted: July 12, 2011 Last Verified: July 2011 Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Methylphenidate Central Nervous System Stimulants Physiological Effects of Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular (...) methylphenidate or Concerta. The specific hypotheses of this study are: Hypothesis 1: ADHD symptomatology in adults with DSM-IV, ADHD will continue to be controlled in patients switched from MPH IR TID to Concerta. Hypothesis 2: Patient satisfaction will not decrease in patients switched from MPH IR TID to Concerta (ie., all patients will be equally or more satisfied on Concerta as compared with MPH IR TID. Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug

2006 Clinical Trials

253. Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)

that cause problem(s) in the home setting. Exclusion Criteria: Have failed to respond to an adequate trial of treatment with an ADHD stimulant medication, bupropion, or other nonstimulant medication. Are taking any antipsychotic medication or mood stabilizers within 8 weeks of Visit 1 Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor (...) Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months) Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2005 Clinical Trials

254. Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy

Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Atomoxetine Hydrochloride Central Nervous System Stimulants Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Adrenergic Agents Neurotransmitter Agents Physiological Effects of Drugs (...) Collaborator: Eli Lilly and Company Information provided by: Massachusetts General Hospital Study Details Study Description Go to Brief Summary: This will be a 6-week, unblinded study using the medication Strattera for children and adolescents with attention deficit hyperactivity disorder (ADHD) who failed to respond to an adequate trial of stimulant treatment. Specific hypotheses are as follows: Hypothesis 1: ADHD symptomatology in youth with ADHD will be responsive to Strattera treatment in the short

2005 Clinical Trials

255. Concerta Treatment in Adults With ADHD NOS

: September 16, 2005 Last Update Posted: July 23, 2010 Last Verified: July 2010 Keywords provided by Massachusetts General Hospital: ADHD NOS Adults Concerta Open-Label Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Atomoxetine Hydrochloride Methylphenidate Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators (...) General Hospital Study Details Study Description Go to Brief Summary: This will be an open label pilot study of Concerta in the treatment of adults with the diagnosis of Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS). We hypothesize ADHD symptomatology in adults with ADHD NOS will be responsive to Concerta treatment in the short term and Concerta-associated response of ADHD symptomatology in adults with ADHD NOS will be sustained over the medium term. Condition or disease

2005 Clinical Trials

256. Major Depression with ADHD: In Children and Adolescents Full Text available with Trip Pro

Major Depression with ADHD: In Children and Adolescents The objective of this paper is to review recent studies on comorbidity and treatment of major depression (MD) and attention deficit/hyperactivity disorder (ADHD) in children and adolescents. Both ADHD and MD are commonly associated with other DSM-IV Axis I psychiatric disorders. ADHD is more commonly associated with oppositional defiant disorder and conduct disorder in children and adolescents. The literature on comorbidities of MD (...) disorders (anxiety disorders, oppositional defiant disorder, conduct disorder) will also be made. The concept of "goodness of fit" as it applies to medication choices will also be outlined. Some antidepressants, such as imipramine, desipramine, and bupropion have been effective in treating major depression, anxiety disorders, and ADHD in adults. Tricyclic antidepressants have not been as effective in treating MD in children and adolescents; however, they can be used to treat adults with ADHD and MD

2006 Psychiatry (Edgmont)

257. ADHD in children and adolescents Full Text available with Trip Pro

ADHD in children and adolescents Prevalence estimates of attention deficit hyperactivity disorder (ADHD) vary according to the diagnostic criteria used and the population sampled. DSM-IV prevalence estimates among school children in the US are 3-5%, but other estimates vary from 1.7% to 16.0%. No objective test exists to confirm the diagnosis of ADHD, which remains a clinical diagnosis. Other conditions frequently co-exist with ADHD.We conducted a systematic review and aimed to answer (...) the following clinical questions: What are the effects of pharmacological treatments for ADHD in children and adolescents? What are the effects of psychological treatments for ADHD in children and adolescents? What are the effects of combination treatments for ADHD in children and adolescents? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version

2008 BMJ Clinical Evidence

258. A Review of Co-Morbid Depression in Pediatric ADHD: Etiology, Phenomenology, and Treatment. Full Text available with Trip Pro

A Review of Co-Morbid Depression in Pediatric ADHD: Etiology, Phenomenology, and Treatment. This paper reviews the literature and highlights the need for further research regarding the phenomenology, etiology, assessment, and treatment of co-morbid depression in patients with attention-deficit/hyperactivity disorders (ADHD). Depression occurs in youths with ADHD at a significantly higher rate than in youths without ADHD. Youths with ADHD and depression together have a more severe course (...) studies for youths with ADHD and co-morbid depression, there is increasing preliminary evidence for the role of stimulants, selective serotonergic reuptake inhibitors, bupropion, and atomoxetine to target either or both disorders. There is also some indirect evidence for the benefit of combining pharmacological treatments with psychosocial interventions that specifically target relevant environmental factors and functional impairments.

2008 Journal of Child and Adolescent Psychopharmacology

259. ADHD treatment across the life cycle. (Abstract)

ADHD treatment across the life cycle. Since attention-deficit/hyperactivity disorder (ADHD) is usually diagnosed in children, evidence from the studies of pharmacologic treatments for children with ADHD is used to inform pharmacologic treatment recommendations for adults. A large percentage of children diagnosed with ADHD have symptoms that persist into adolescence and adulthood. Evidence shows that pharmacologic treatments improve functional outcomes in children with ADHD, and studies using (...) similar pharmacologic treatments show positive results in adults with ADHD. This article reviews the use of long-acting methylphenidate, mixed amphetamine salts, desipramine, monoamine oxidase inhibitors, bupropion, and atomoxetine in studies of children, adolescents, and adults with ADHD.

2004 Journal of Clinical Psychiatry

260. Impact of ADHD and its treatment on substance abuse in adults. (Abstract)

Impact of ADHD and its treatment on substance abuse in adults. Attention-deficit/hyperactivity disorder (ADHD) is a risk factor for substance abuse in adults. Additional psychiatric comorbidity increases this risk. ADHD is associated with different characteristics of substance abuse: substance abuse transitions more rapidly to dependence, and lasts longer in adults with ADHD than those without ADHD. Self-medication may be a factor in the high rate of substance abuse in adults with ADHD. While (...) previous concerns arose whether stimulant therapy would increase the ultimate risk for substance abuse, recent studies have indicated that pharmacologic treatment appears to reduce the risk of substance abuse in individuals with ADHD. When treating adults with ADHD and substance abuse, clinicians should assess the relative severity of the substance abuse, the symptoms of ADHD, and any other comorbid disorders. Generally, stabilizing or addressing the substance abuse should be the first priority when

2004 Journal of Clinical Psychiatry

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>